Utility of the Milan System for Reporting Salivary Gland Cytology, with focus on the incidence and histologic correlates of atypia of undetermined significance (AUS) and salivary gland neoplasm of uncertain malignant potential (SUMP): A 3-year institutional experience

被引:8
|
作者
Cormier, Christopher M. [1 ]
Agarwal, Shweta [1 ]
机构
[1] Univ New Mexico, Dept Pathol, Sch Med, Albuquerque, NM 87131 USA
关键词
atypia of undetermined significance (AUS); fine-needle aspiration; Milan system; risk of malignancy; salivary gland neoplasm of uncertain malignant potential (SUMP); salivary gland; NEEDLE-ASPIRATION-CYTOLOGY; CYTOPATHOLOGY; RISK; LESIONS; ACCURACY;
D O I
10.1002/cncy.22538
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Fine-needle aspiration (FNA) is the preferred diagnostic test for salivary gland lesions. The purpose of the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is to standardize salivary gland cytology reporting and guide treatment decisions. The objective of the current study was to evaluate the utility and performance of the MSRSGC, with a focus on the cytomorphology of lesions diagnosed as atypia of undetermined significance (AUS) and salivary gland neoplasm of uncertain malignant potential (SUMP). Methods In total, 123 salivary gland FNAs were included in the study. FNA diagnoses for all cases were reviewed and recategorized, as applicable, according to the MSRSGC. Cytohistologic correlation was performed in 51 cases that had available surgical follow-up, and the risk of malignancy (ROM) was calculated. Results Most FNA samples were from the parotid gland. The mean patient age was 61.4 years, and the male-to-female ratio was 1.3:1. The ROM was 0% (categories I and II; nondiagnostic and benign nonneoplastic, respectively), 50% (category III; AUS), 0% (category IVA; benign neoplasm), 40% (category IVB; SUMP), 100% (category V; suspicious for malignancy), and 100% (category VI; malignant). Sensitivity, specificity, positive predictive value, and negative predictive value were 100% each. In addition, the primary factors for an AUS diagnosis were identified as low cellularity and/or the presence of lymphocytes. The presence of oncocytes followed by cellular atypia in an otherwise classic pleomorphic adenoma were principal factors for a SUMP diagnosis. Conclusions The authors report an ROM comparable to that reported in the literature, with a sensitivity and specificity of 100%, supporting adaptation of the MSRSGC into the system for reporting salivary gland cytology. In addition, the findings emphasize the need to refine criteria for AUS and SUMP, thereby improving the predictive capability and subsequent management of salivary gland lesions.
引用
收藏
页码:303 / 312
页数:10
相关论文
共 14 条
  • [1] How important are the cytomorphologic subtypes of the salivary gland neoplasm of uncertain malignant potential (SUMP) category in the Milan system for reporting salivary gland cytology? An institutional experience 2018-2024
    Arisi, Maria Florencia
    Jin, Xueting
    Ravish, Nakul A.
    Chand, Momal T.
    Baloch, Zubair
    DIAGNOSTIC CYTOPATHOLOGY, 2024, 52 (11) : 662 - 670
  • [2] Subcategorizing salivary gland neoplasm of uncertain malignant potential (SUMP) in the Milan System for Reporting Salivary Gland Cytopathology
    Pusztaszeri, Marc P.
    Baloch, Zubair W.
    CANCER CYTOPATHOLOGY, 2022, 130 (07) : 484 - 487
  • [3] Analysis of Histologic Follow-Up and Risk of Malignancy for Salivary Gland Neoplasm of Uncertain Malignant Potential Proposed by the Milan System for Reporting Salivary Gland Cytopathology
    Liu, Haiyan
    Ljungren, Clarissa
    Lin, Fan
    Zarka, Matthew A.
    Chen, Longwen
    CANCER CYTOPATHOLOGY, 2018, 126 (07) : 490 - 497
  • [4] Risk of Malignancy Associated With Cytomorphology Subtypes in the Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) Category in the Milan System: A Bi-Institutional Study
    Chowsilpa, Sayanan
    An, Daniel
    Lose, Holly
    Huang, Xiao
    Nayar, Ritu
    Maleki, Zahra
    CANCER CYTOPATHOLOGY, 2019, 127 (06) : 377 - 389
  • [5] Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) (Milan IVB) and Its Subgroups: A Multi-Institutional Analysis of Risk of Neoplasm and Malignancy
    Xia, Rong
    Hindi, Issa
    Savant, Deepika
    Khader, Samer
    Lajara, Sigfred
    Belovarac, Brendan
    Das, Kasturi
    Chau, Karen
    Abdelwahed, Mohammed
    Ali, Amr
    Szeto, Oliver
    Hernandez, Osvaldo
    Sun, Wei
    Liu, Cheng Z.
    Zhou, Fang
    Simsir, Aylin
    Brandler, Tamar C.
    DIAGNOSTIC CYTOPATHOLOGY, 2024, 52 (12) : 756 - 762
  • [6] Risk stratification and clinical outcome in the atypia of undetermined significance category in the Milan System for Reporting Salivary Gland Cytopathology
    Wangsiricharoen, Sintawat
    Maleki, Zahra
    CANCER CYTOPATHOLOGY, 2021, 129 (02) : 132 - 139
  • [7] A retrospective 3-year study of salivary gland FNAC with categorisation using the Milan reporting system
    Thiryayi, S. A.
    Low, Y. X.
    Shelton, D.
    Narine, N.
    Slater, D.
    Rana, D. N.
    CYTOPATHOLOGY, 2018, 29 (04) : 343 - 348
  • [8] Multi-institutional validation of a modified scheme for subcategorizing salivary gland neoplasm of uncertain malignant potential (SUMP)
    Hang, Jen-Fan
    Lee, Jaslyn Jie Lin
    Nga, Min En
    Higuchi, Kayoko
    Hirata, Yukiya
    Wu, Howard H.
    Allison, Derek B.
    Gilbert, Jason D.
    Lin, Oscar
    Saieg, Mauro
    de Arruda, Arthur Ferrari
    Chen, Yun-An
    Huang, Eric C.
    Manucha, Varsha
    CANCER CYTOPATHOLOGY, 2022, 130 (07) : 511 - 522
  • [9] The Role of the Milan System for Reporting Salivary Gland Cytopathology: A 5-Year Institutional Experience
    Viswanathan, Kartik
    Sung, Simon
    Scognamiglio, Theresa
    Yang, Grace C. H.
    Siddiqui, Momin T.
    Rao, Rema A.
    CANCER CYTOPATHOLOGY, 2018, 126 (08) : 541 - 551
  • [10] A Retrospective Cytomorphologic Analysis of Salivary Gland Fine Needle Aspirates Classified as Salivary Gland Neoplasm of Uncertain Malignant Potential: A 6-year Institutional Experience
    Agarwal, Shweta
    DIAGNOSTIC CYTOPATHOLOGY, 2024, 52 (12) : 738 - 746